Bitcoin

The trial is part of a broader wave of longevity biotech that could reshape demographic and economic assumptions over decades—potentially affecting long-term asset allocation. In the near term, however, crypto markets are driven by liquidity, regulatory noise, and macro fears; a single clinical milestone is unlikely to move capital flows. Moreover, the extreme bearish sentiment suggests traders are ignoring non-crypto narratives entirely.

First participant treated in landmark clinical trial of cellular reprogramming therapy to rejuvenate ageing cells.